Ebola outbreak in DRC escalates as global response struggles

Five weeks after its declaration, the Ebola Bundibugyo outbreak in the Democratic Republic of Congo (DRC) remains far from contained. While the response has intensified, the virus continues to spread across borders, claiming lives at an alarming rate.

Response gains momentum but falls short

The efforts to combat the epidemic have expanded significantly. Treatment capacity has surged from fewer than 10 beds to over 500 across 19 health centers in affected areas. Daily testing has followed a similar trajectory, rising from 30 tests at the outbreak’s start to more than 2,000 per day across nine laboratories in three provinces. Over 100 recoveries have been recorded, proving that early intervention can save lives.

Yet the overall toll remains devastating: 1,094 confirmed cases and 277 deaths to date. According to the World Health Organization (WHO), the outbreak continues to outpace the response. Contact tracing remains inadequate, isolation capabilities fall short of demand, and secure burials remain a daily challenge in communities that are often mistrustful or inaccessible.

A virus crossing borders

The epidemic has now spread far beyond the DRC’s Ituri, North Kivu, and South Kivu provinces. Neighboring Uganda has reported 20 confirmed cases and two deaths, all linked to the Congolese strain. Even more alarmingly, France confirmed its first case on Wednesday—a humanitarian doctor from the NGO ALIMA, who had returned from a mission in the DRC and tested positive for the Ebola Bundibugyo virus. The doctor, currently receiving specialized care in stable condition, is the subject of an ongoing epidemiological investigation to identify and monitor contacts.

This case underscores the sacrifices made by frontline health workers. Nearly 80 health workers have been infected since the crisis began, prompting the WHO to urge states to ensure secure deployment conditions for humanitarian personnel, including the possibility of rapid medical evacuation in case of contamination.

Structural hurdles hamper containment efforts

Beyond health challenges, the response faces structural barriers that hinder every intervention. Border closures impede the movement of teams and equipment. Security incidents are on the rise in a region plagued by decades of armed conflict. And funding has been slow to materialize, even as the WHO and Africa CDC launched a continental plan totaling $518 million.

Hope on the horizon

One promising development is the imminent launch of a clinical trial evaluating two antivirals, MBP134 and remdesivir. Scheduled to begin next week in the DRC, the trial is led by a consortium including the Congolese National Institute of Biomedical Research, ALIMA, the University of Oxford, and the WHO. Support from the United States and Gilead Sciences further bolsters the initiative. This trial could mark a turning point in the fight against an epidemic that, five weeks after its onset, shows no signs of abating.

Key takeaways

• Treatment capacity: Expanded from fewer than 10 beds to over 500 across 19 centers.
• Testing capabilities: Increased from 30 to over 2,000 daily tests across nine laboratories.
• Global spread: Cases reported in Uganda and France, highlighting the virus’s international reach.
• Health worker impact: Nearly 80 infections among frontline workers, underscoring the need for secure deployment conditions.
• Funding gap: A $518 million continental plan remains underfunded.
• Clinical trial: Antiviral trial (MBP134 and remdesivir) to launch next week in the DRC.